NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sage securities between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"). Investors h ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ: SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage secu ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"). For more information, submit a form at Sage Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallo ...

LOS ANGELES, Aug. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ: SAGE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), ...

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), have until October 28, 2024 to seek appointment as lead plaintiff of the Sage Therapeutics class action lawsuit. Captioned Korver v. Sage Therapeutics, Inc., No. 24-cv06511 (S.D.N.Y.), the Sage Therapeutics class action lawsuit charges Sage Therapeutics and certain of ...

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage Therapeutics" or "the Company") (NASDAQ: SAGE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (i) zuranolone was less effective in treating major depressive disorder ("MDD") than Defendants had led investo ...

Sage Therapeutics, Inc. (SAGE) reported a loss of $1.70 per share for the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.68. The company had reported a loss of $2.68 per share in the year-ago quarter. Revenues in the second quarter totaled $8.6 million, significantly up from $2.5 million reported in the year-ago period. The upside can be attributed to strong uptake for the recently launched depression drug Zurzuvae (zuranolone), which is marketed in partnership with drug gia ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. How Have t ...

The company's first marketed drug, Zulresso (brexanolone), was approved by the FDA in 2019 as the first-ever FDA-approved treatment for adults with postpartum depression (PPD). SAGE markets Zurzuvae in partnership with drug giant Biogen (BIIB) . Sage and BIIB are focused on establishing Zurzuvae as a first-line therapy and the standard of care for women with PPD. Image Source: Zacks Investment Research Last month, the company reported that the phase II SURVEYOR study evaluating dalzanemdor as a potential tr ...

Sage Therapeutics (SAGE) announced that the phase II SURVEYOR study evaluating its lead neuropsychiatric candidate, dalzanemdor (SAGE-718), as a potential treatment for patients with cognition dysfunction caused by Huntington's disease (HD), met its primary endpoint. Shares of the company were however down 2.8% on Jun 11 following the announcement of the news. The SURVEYOR study compared dalzanemdor versus placebo in participants with HD for a 28-day treatment period. The three main objectives of the SURVEY ...